Vogt Frederick G's Form 4 filing
Iovance Biotherapeutics, Inc. (IOVA) · filed Sep 10, 2026
- Accession no.
- 0001104659-26-106752
- Filed
- Sep 10, 2026, 5:01 PM ET
- Trade date
- Sep 8, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vogt Frederick GCIK 0001719678 | Director, Officer (Interim CEO & General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Common Stock | MOption exerciseAcquired | +15,626 | $0.00 | $0 | 602,085 | Direct | |
| Sep 8, 2026 | Common Stock | FTax withholdingDisposed | −6,638 | $8.70 | −$57,750.6 | 595,447 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Common stock | MOption exerciseDisposed | −15,626 | $0.00 | $0 | 93,756 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.